Discover the latest industry insights at the 2025 Annual Meeting through engaging educational and product-focused sessions. These presentations give exhibiting companies a platform to unveil ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

Initiating methotrexate within 2 years of a psoriasis diagnosis is associated with a reduced risk of progressing to PsA.

Dermatologists are practicing in an “era of good efficacy” of nonsteroidal topical therapies for psoriasis, and they can help patients access newer topical medications by working with pharmacies that ...

Samsung Bioepis Co., Ltd. today announced that PYZCHIVA ® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been approved for the treatment ...

Psoriasis is a skin condition that affects millions of people worldwide. It causes red, itchy, and scaly patches, usually on ...

Despite these limitations, the researchers believe the study confirmed the efficacy and safety of bimekizumab and brodalumab ...

Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.

A diet of fruits and vegetables, whole grains, low-fat dairy foods and lean meats, low in salt and sugar, is associated with ...

Patients with psoriasis, psoriatic arthritis, and axial spondylarthritis using ixekizumab have a low incidence rate of cerebro-cardiovascular events.

Teva (TEVA) stock and Alvotech (ALVO) stock in focus as duo launches Selarsdi, a biosimilar to J&J's (JNJ) Stelara after a ...

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...